At Genprex, the health and well-being of the communities we serve, including those with cancer and diabetes, is our top priority.
March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.
Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.
Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.
Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.
Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is researching and developing therapies for the treatment of lung cancer….
Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.
Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2….
Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.
Gene therapies and immunotherapies are two different types of treatment….
Pfizer recently announced its plans to invest $500 million into its Sanford gene therapy manufacturing operations. This expansion would create 300 new jobs, and Pfizer’s biopharmaceuticals group president noted the company “passionately believes in gene therapy.”
This passion for gene therapy, which is seemingly shared with other large biopharma companies, is leading to substantial commitments of resources to gene therapy….
Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….